Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Tumor Nutritional Therapy Combined With Immune Checkpoint Inhibitors and Chemotherapy in the First-line Treatment of Stage IV NSCLC Without Driver Gene Mutations

NCT06356701 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Dalian Medical University as lead sponsor.

NCT NCT06356701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06356701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Tumor Nutritional Therapy Combined With Immune Checkpoint Inhibitors and Chemotherapy in the First-line Treatment of Stage IV NSCLC Without Driver Gene Mutations
Lead sponsor
The First Affiliated Hospital of Dalian Medical University
Phase
Phase 1
Overall status
Unknown status
Start date
April 15, 2024
Completion date
December 31, 2025
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long-term effects secondary to cancer therapy